Lipkin Study Press Conference 18th Sept

VillageLife

Senior Member
Messages
674
Likes
36
Location
United Kingdom
From ME/CFS forums.....

The press conference will be held on Sept. 18th from approximately 11:00am to noon. It will be streamed our website (cii.columbia.edu), and you can expect an announcement on our website/Twitter (@CII722) with links to the specific pages on Friday/Monday.


------------------
EDIT
------------------

http://cii.columbia.edu/blog.htm?LOfRcb

CII Press Conference

September 18th, 2012

10:30 AM (EDT)

“Multicenter Study on Chronic Fatigue Syndrome/Myalgic Encephalomyelitis”

The causes of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) have long eluded scientists. In 2009/2010, two high-profile papers linked the syndrome to infection with a mouse retrovirus called XMRV (xenotropic murine leukemia virus (MLV)-related virus) and murine retrovirus-like sequences (designated pMLV: polytropic MLV). Given that affected patients often have symptoms consistent with a chronic infection, this viral connection was deemed plausible, and the findings were celebrated as a major achievement for a complex disease that afflicts nearly 1 million in the U.S.

However, follow-up investigations by several laboratories were unable to detect XMRV or pMLV in CFS patients.

To definitively resolve this issue, the National Institute of Allergy and Infectious Diseases commissioned a large-scale, multicenter study under the auspices of the Center for Infection and Immunity at Columbia University’s Mailman School of Public Health, in partnership with the Centers for Disease Control and Prevention, the Food and Drug Administration, the NIH’s National Cancer Institute and Warren G. Magnuson Clinical Center, and others (see full list below).

Investigators from the multicenter study on CFS/ME and XMRV/pMLV will discuss their findings and future directions.

A live video will be posted below.

For attendance at the event, members of the media should RSVP by 9:00AM on Monday, Sept. 17th to Nsikan Akpan (212-342-9051 | nea2107@columbia.edu) or Stephanie Berger, Mailman School of Public Health (212-305-4372 | sb2247@columbia.edu).

When: Tuesday, September 18, 2012

Press Conference begins at 10:30 AM (EDT)

Who: W. Ian Lipkin, MD (Moderator)

Center for Infection and Immunity (CII), Mailman School of Public Health, Columbia University

Principal Investigator and Director of Center for Infection and Immunity

John Snow Professor of Epidemiology

Professor of Neurology and Pathology



Harvey Alter, MD

National Institutes of Health, Department of Transfusion Medicine

Distinguished NIH Investigator

Chief, Clinical Studies

Associate Director of Research



Mady Hornig, MD

Center for Infection and Immunity, Mailman School of Public Health, Columbia University

Director of Translational Research at CII

Associate Professor of Epidemiology



Judy Mikovits, PhD

Mikovits Consulting



Francis Ruscetti, PhD

National Cancer Institute, Frederick National Laboratory for Cancer Research

Head, Leukocyte Biology Section

Senior Investigator

Collaborating Research Groups:

Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD.
Mikovits Consulting, Oxnard, CA.
Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA.
Cancer and Inflammation Program, Frederick National Laboratory for Cancer Research, Frederick, MD.
Tissue Safety Laboratory, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD.
Nova Southeastern University, Fort Lauderdale FL.
Miami Veterans Affairs Medical Center, Miami, FL.
Brigham and Women’s Hospital, Boston, MA.
Infectious Disease Clinic, Stanford University, Palo Alto, CA.
Fatigue Consultation Clinic, Salt Lake City, UT.
Levine Clinic, New York, NY.
Simmaron Research Institute, Incline Village, NV.
Department of Biostatistics, Columbia University, New York, NY.
Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY.
Center for Infection and Immunity, Columbia University, New York, NY.
Department of Molecular Biology and Microbiology, Tufts University, Boston, MA.
 

Esther12

Senior Member
Messages
13,774
Likes
28,350
I wonder how much press attention this will get now, and how the results will be presented. I guess I'll find out soon. Ta VL.
 

barbc56

Senior Member
Messages
3,656
Likes
4,953
Do you know where this announcment originated.? Was the twitter account the first time this was reported or was there a press release?. Obviously, I don't know that much about twitter. Thanks!!
Barb C.>:)
 

snowathlete

Senior Member
Messages
5,374
Likes
14,592
Location
UK
Timezone?

I would think that regardless of the result it will get good press partly because of Lipkins status. That is one of the greatest benefits to having Lipkin inboard working on ME because he is so well regarded and connected.
 

Bob

Senior Member
Messages
16,455
Likes
34,041
Location
England (south coast)
I don't know what the source of this message is, but the full message, as found on ProHealth, is as follows:

Columbia to Hold XMRV Press Conference Sep 18

The findings of a study of virus involvement in ME/CFS patient samples, led by Columbia University 'virus hunter' Ian Lipkin, will be streamed live starting at 10:00 or 11:00 AM Eastern Time on September 18, according to a note from Columbia's Center for Infection and Immunity (CII). The live press conference will be found on the CII website (www.cii.columbia.edu), and an official announcement of the event reportedly will appear on the CII's facebook page within a few days.

http://www.prohealth.com/library/showarticle.cfm?libid=17200
 

August59

Daughters High School Graduation
Messages
1,617
Likes
627
Location
Upstate SC, USA
Kind of nice to see it being released this way. I imagine there will be a lot of questions remaining at the end of the webcast so, hopefully the entire paper will be availble at that time or shortly there after.
 

Wally

Senior Member
Messages
888
Likes
1,902
Do you know where this announcment originated.? Was the twitter account the first time this was reported or was there a press release?. Obviously, I don't know that much about twitter. Thanks!!
Barb C.>:)
As far as I could tell the announcement first came out on the CII Twitter account and then on their Facebook page. I didn't find any similar announcement on their website even though there is a "media" and "latest news" section. A bit confused myself on how "official" public information is disseminated when an organization is using multiple social media platforms.
 

Mula

Senior Member
Messages
131
Likes
46
The current fashion is to publish links on multiple media hosts.

Do I follow, that you are unable to find where this message originated?
 

ukxmrv

Senior Member
Messages
4,406
Likes
4,569
Location
London
I checked their twitter account and their facebook page but couldn't find it. The posting seems to have started on another patient forum. I'm wondering if it was an email to an individual.
 

shannah

Senior Member
Messages
1,421
Likes
1,725
http://cii.columbia.edu/blog.htm?LOfRcb

CII Press Conference

September 18th, 2012

10:30 AM (EDT)

“Multicenter Study on Chronic Fatigue Syndrome/Myalgic Encephalomyelitis”

The causes of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) have long eluded scientists. In 2009/2010, two high-profile papers linked the syndrome to infection with a mouse retrovirus called XMRV (xenotropic murine leukemia virus (MLV)-related virus) and murine retrovirus-like sequences (designated pMLV: polytropic MLV). Given that affected patients often have symptoms consistent with a chronic infection, this viral connection was deemed plausible, and the findings were celebrated as a major achievement for a complex disease that afflicts nearly 1 million in the U.S.​

However, follow-up investigations by several laboratories were unable to detect XMRV or pMLV in CFS patients.

To definitively resolve this issue, the National Institute of Allergy and Infectious Diseases commissioned a large-scale, multicenter study under the auspices of the Center for Infection and Immunity at Columbia University’s Mailman School of Public Health, in partnership with the Centers for Disease Control and Prevention, the Food and Drug Administration, the NIH’s National Cancer Institute and Warren G. Magnuson Clinical Center, and others (see full list below).

Investigators from the multicenter study on CFS/ME and XMRV/pMLV will discuss their findings and future directions.

A live video will be posted below.

For attendance at the event, members of the media should RSVP by 9:00AM on Monday, Sept. 17th to Nsikan Akpan (212-342-9051 | nea2107@columbia.edu) or Stephanie Berger, Mailman School of Public Health (212-305-4372 | sb2247@columbia.edu).

When: Tuesday, September 18, 2012

Press Conference begins at 10:30 AM (EDT)

Who: W. Ian Lipkin, MD (Moderator)

Center for Infection and Immunity (CII), Mailman School of Public Health, Columbia University

Principal Investigator and Director of Center for Infection and Immunity

John Snow Professor of Epidemiology

Professor of Neurology and Pathology



Harvey Alter, MD

National Institutes of Health, Department of Transfusion Medicine

Distinguished NIH Investigator

Chief, Clinical Studies

Associate Director of Research



Mady Hornig, MD

Center for Infection and Immunity, Mailman School of Public Health, Columbia University

Director of Translational Research at CII

Associate Professor of Epidemiology



Judy Mikovits, PhD

Mikovits Consulting



Francis Ruscetti, PhD

National Cancer Institute, Frederick National Laboratory for Cancer Research

Head, Leukocyte Biology Section

Senior Investigator

Collaborating Research Groups:

  • Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD.
  • Mikovits Consulting, Oxnard, CA.
  • Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA.
  • Cancer and Inflammation Program, Frederick National Laboratory for Cancer Research, Frederick, MD.
  • Tissue Safety Laboratory, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD.
  • Nova Southeastern University, Fort Lauderdale FL.
  • Miami Veterans Affairs Medical Center, Miami, FL.
  • Brigham and Women’s Hospital, Boston, MA.
  • Infectious Disease Clinic, Stanford University, Palo Alto, CA.
  • Fatigue Consultation Clinic, Salt Lake City, UT.
  • Levine Clinic, New York, NY.
  • Simmaron Research Institute, Incline Village, NV.
  • Department of Biostatistics, Columbia University, New York, NY.
  • Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY.
  • Center for Infection and Immunity, Columbia University, New York, NY.
  • Department of Molecular Biology and Microbiology, Tufts University, Boston, MA.
 

Sasha

Fine, thank you
Messages
17,863
Likes
34,206
Location
UK
Investigators from the multicenter study on CFS/ME and XMRV/pMLV will discuss their findings and future directions.
That sounds promising - "future directions" - at the very least there'll be some "future directions"...
 

urbantravels

disjecta membra
Messages
1,333
Likes
521
Location
Los Angeles, CA
It's the negative results from the Lipkin study.
That's what I think too. What I don't understand is making so much hoop-la about it if they only have a negative result to report, one that only confirms previous and very reputable negative results. I'd just as soon they be low-key about it if that's the case.

The reason for hoop-la may be that they found something else [but that doesn't seem likely considering the study design, and I don't think there are many left that believe there's a SINGLE pathogen] or....(2) to make sure Judy Mikovits is standing shoulder to shoulder with the other investigators and confirming that she agrees with the result. After all, wasn't that a condition of the study -- that all investigators should reach 100% consensus before publication?

So my biggest question remains ... what else COULD they have found within the scope of the study?
 

Esther12

Senior Member
Messages
13,774
Likes
28,350
It could well be that they think CFS patients are more committed to XMRV as a cause than is truly the case, as the only CFS patients they are likely to have heard from in the last 12 months are those who are still committed to XMRV as a cause of CFS. If they think they've got a roughly representative sample, then they will think that these results are a big deal. (Not to do this study down - it is good that a really thorough blinded study was done, it just would have been nice if this was done three years ago instead).

I think you're right about them wanting Mikovits to be there to, ideally answering questions as well. With he publicly accepting that her initial work was flawed, and explaining how she knows this to be the case, it will be hard for anyone to keep acting as if XMRV is a likely cause of CFS.